[
  {
    "ts": null,
    "headline": "A Look At Johnson & Johnson (JNJ) Valuation After New Long Term TREMFYA Ulcerative Colitis Data",
    "summary": "Johnson & Johnson (JNJ) is in focus after releasing long term QUASAR study data showing TREMFYA sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis. See our latest analysis for Johnson & Johnson. Despite a 1 day share price return of 1.79% decline to US$242.49 and some recent legal and competitive headlines, investors have still seen a 90 day share price return of 17.69% and a 1 year total shareholder return...",
    "url": "https://finnhub.io/api/news?id=2bd082991aba7a04e4cc8fcb305140d18fc85505e65fb22dd964edd1fd302045",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771870419,
      "headline": "A Look At Johnson & Johnson (JNJ) Valuation After New Long Term TREMFYA Ulcerative Colitis Data",
      "id": 139187241,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) is in focus after releasing long term QUASAR study data showing TREMFYA sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis. See our latest analysis for Johnson & Johnson. Despite a 1 day share price return of 1.79% decline to US$242.49 and some recent legal and competitive headlines, investors have still seen a 90 day share price return of 17.69% and a 1 year total shareholder return...",
      "url": "https://finnhub.io/api/news?id=2bd082991aba7a04e4cc8fcb305140d18fc85505e65fb22dd964edd1fd302045"
    }
  },
  {
    "ts": null,
    "headline": "Bloomberg Reports Potential Major Asset Sale by Johnson & Johnson (JNJ)",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. On February 20, Bloomberg reported that Johnson & Johnson (NYSE:JNJ) is exploring a possible sale of its orthopedics unit, DePuy Synthes, as part of its broader separation plan. According to people familiar with the matter, several large buyout […]",
    "url": "https://finnhub.io/api/news?id=b764c0328be3961b26fa4b41ec1950bac3499a6068a6bc9dc4c7c030b5459d61",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771870311,
      "headline": "Bloomberg Reports Potential Major Asset Sale by Johnson & Johnson (JNJ)",
      "id": 139187242,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. On February 20, Bloomberg reported that Johnson & Johnson (NYSE:JNJ) is exploring a possible sale of its orthopedics unit, DePuy Synthes, as part of its broader separation plan. According to people familiar with the matter, several large buyout […]",
      "url": "https://finnhub.io/api/news?id=b764c0328be3961b26fa4b41ec1950bac3499a6068a6bc9dc4c7c030b5459d61"
    }
  },
  {
    "ts": null,
    "headline": "Bayer sues Johnson & Johnson over marketing of prostate cancer drug",
    "summary": "NEW YORK, Feb 23 () - Bayer sued Johnson & Johnson ‌on Monday, accusing ‌the rival drugmaker of falsely advertising ​a drug intended to treat prostate cancer. According to a complaint filed in Manhattan ‌federal court, ⁠Johnson & Johnson launched a false advertising campaign against ⁠Bayer's Nubeqa drug, in order to promote and ​demonstrate the ​alleged ​superiority of its ‌own drug, Erleada.",
    "url": "https://finnhub.io/api/news?id=b0e7bb7556e633c58001894183f932f28bb3490b8e65182e478cd19ae94bf890",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771862984,
      "headline": "Bayer sues Johnson & Johnson over marketing of prostate cancer drug",
      "id": 139186372,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "NEW YORK, Feb 23 () - Bayer sued Johnson & Johnson ‌on Monday, accusing ‌the rival drugmaker of falsely advertising ​a drug intended to treat prostate cancer. According to a complaint filed in Manhattan ‌federal court, ⁠Johnson & Johnson launched a false advertising campaign against ⁠Bayer's Nubeqa drug, in order to promote and ​demonstrate the ​alleged ​superiority of its ‌own drug, Erleada.",
      "url": "https://finnhub.io/api/news?id=b0e7bb7556e633c58001894183f932f28bb3490b8e65182e478cd19ae94bf890"
    }
  },
  {
    "ts": null,
    "headline": "Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA",
    "summary": "WHIPPANY, N.J., February 23, 2026--Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA",
    "url": "https://finnhub.io/api/news?id=35834fcf581e88eb2c17fbda7f0cda5c4155893917c31c65b2aa6b6581c44cc3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771860480,
      "headline": "Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA",
      "id": 139185145,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "WHIPPANY, N.J., February 23, 2026--Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA",
      "url": "https://finnhub.io/api/news?id=35834fcf581e88eb2c17fbda7f0cda5c4155893917c31c65b2aa6b6581c44cc3"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J",
    "summary": "Gilead Sciences is buying Arcellx for $7.8 billion. The companies are already working together on a multiple myeloma drug.",
    "url": "https://finnhub.io/api/news?id=3d5feb0aa8d3e40768b93d8c0383426e27b992c41dfacaf1206b31e139d8fe60",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771860380,
      "headline": "Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J",
      "id": 139185146,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Gilead Sciences is buying Arcellx for $7.8 billion. The companies are already working together on a multiple myeloma drug.",
      "url": "https://finnhub.io/api/news?id=3d5feb0aa8d3e40768b93d8c0383426e27b992c41dfacaf1206b31e139d8fe60"
    }
  },
  {
    "ts": null,
    "headline": "What's in Store for These 5 Medical Companies This Earnings Season?",
    "summary": "IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.",
    "url": "https://finnhub.io/api/news?id=7884f2c87cb0f77ade9a77c1c8a5dc1a6fdc8ee80361015fff97667392aff78d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771855620,
      "headline": "What's in Store for These 5 Medical Companies This Earnings Season?",
      "id": 139185147,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.",
      "url": "https://finnhub.io/api/news?id=7884f2c87cb0f77ade9a77c1c8a5dc1a6fdc8ee80361015fff97667392aff78d"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Falls On New Trump Tariffs; Novo Plunges On Drug Trial Results (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index dropped Monday on higher Trump tariffs. Novo stock plunged on weight-loss drug trial results.",
    "url": "https://finnhub.io/api/news?id=635e84af3373b485c764a864bbc9d602792ef4c29d307c64e897db8ce35169d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771854368,
      "headline": "Stock Market Today: Dow Falls On New Trump Tariffs; Novo Plunges On Drug Trial Results (Live Coverage)",
      "id": 139183628,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Stock Market Today: The Dow Jones index dropped Monday on higher Trump tariffs. Novo stock plunged on weight-loss drug trial results.",
      "url": "https://finnhub.io/api/news?id=635e84af3373b485c764a864bbc9d602792ef4c29d307c64e897db8ce35169d2"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Bets Big On Anito-Cel With $7.8 Billion Arcellx Deal",
    "summary": "Gilead Sciences announced an agreement to acquire Arcellx for $115 in cash per share, a 79% premium to the biotech's Friday close.  Gilead will pay an additional $5 per share if sales of its top drug, anito-cell, total at least $6 billion through 2029.  ACLX stock vaulted higher in early Monday stock market action, while GILD dipped slightly.",
    "url": "https://finnhub.io/api/news?id=50ef26f19504e2026e8340e2f4ef079e70209e21fce93eca09179ace3a2f9307",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771854258,
      "headline": "Gilead Bets Big On Anito-Cel With $7.8 Billion Arcellx Deal",
      "id": 139183692,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Gilead Sciences announced an agreement to acquire Arcellx for $115 in cash per share, a 79% premium to the biotech's Friday close.  Gilead will pay an additional $5 per share if sales of its top drug, anito-cell, total at least $6 billion through 2029.  ACLX stock vaulted higher in early Monday stock market action, while GILD dipped slightly.",
      "url": "https://finnhub.io/api/news?id=50ef26f19504e2026e8340e2f4ef079e70209e21fce93eca09179ace3a2f9307"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs",
    "summary": "JNJ's diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with ABBV for healthcare dominance.",
    "url": "https://finnhub.io/api/news?id=299a1f5028806d5b568bfe15d2c4117b1d688b24e4e7f176ecb8064baf34145f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771852380,
      "headline": "Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs",
      "id": 139185148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ's diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with ABBV for healthcare dominance.",
      "url": "https://finnhub.io/api/news?id=299a1f5028806d5b568bfe15d2c4117b1d688b24e4e7f176ecb8064baf34145f"
    }
  },
  {
    "ts": null,
    "headline": "Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer",
    "summary": "Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all previously approved IV indications, offering fewer administration-related reactions and new dosing options1,2,3,4,5,6 BEERSE, BELGIUM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced that the European Commission (EC) has approved an extension of the RYBREVANT®▼ (amivantamab) marke",
    "url": "https://finnhub.io/api/news?id=6b4d3391ab4157a63419e903b91b80e9b5bd763ed3520fe899c5b75216ace942",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771851840,
      "headline": "Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer",
      "id": 139183693,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all previously approved IV indications, offering fewer administration-related reactions and new dosing options1,2,3,4,5,6 BEERSE, BELGIUM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced that the European Commission (EC) has approved an extension of the RYBREVANT®▼ (amivantamab) marke",
      "url": "https://finnhub.io/api/news?id=6b4d3391ab4157a63419e903b91b80e9b5bd763ed3520fe899c5b75216ace942"
    }
  },
  {
    "ts": null,
    "headline": "Want To Simplify Investing? Buy These 2 ETFs And Let America Do The Work",
    "summary": "Want To Simplify Investing? Buy These 2 ETFs And Let America Do The Work",
    "url": "https://finnhub.io/api/news?id=b7a28989642cbd960fa9f14fefb6b132f0bd3469d962e5e9d167e36da8d19bd7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771849843,
      "headline": "Want To Simplify Investing? Buy These 2 ETFs And Let America Do The Work",
      "id": 139186091,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b7a28989642cbd960fa9f14fefb6b132f0bd3469d962e5e9d167e36da8d19bd7"
    }
  },
  {
    "ts": null,
    "headline": "Blackstone Life Sciences Announces a Co-Funding Agreement for Acute Myeloid Leukemia",
    "summary": "CAMBRIDGE, Mass., February 23, 2026--Blackstone Life Sciences (\"BXLS\") today announced a research and development funding agreement to advance the clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor, for acute myeloid leukemia (\"AML\"). AML is the most common type of acute leukemia in adults, yet continues to be extremely challenging to treat, with the lowest survival of all leukemia types.",
    "url": "https://finnhub.io/api/news?id=de1f91bfe9886c9abc5e1e3b9374b37e420178e02792d4f65ea92105372e3b89",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771848000,
      "headline": "Blackstone Life Sciences Announces a Co-Funding Agreement for Acute Myeloid Leukemia",
      "id": 139183694,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "CAMBRIDGE, Mass., February 23, 2026--Blackstone Life Sciences (\"BXLS\") today announced a research and development funding agreement to advance the clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor, for acute myeloid leukemia (\"AML\"). AML is the most common type of acute leukemia in adults, yet continues to be extremely challenging to treat, with the lowest survival of all leukemia types.",
      "url": "https://finnhub.io/api/news?id=de1f91bfe9886c9abc5e1e3b9374b37e420178e02792d4f65ea92105372e3b89"
    }
  },
  {
    "ts": null,
    "headline": "What Gilead Is Getting Through The Acquisition Of Arcellx",
    "summary": "What Gilead Is Getting Through The Acquisition Of Arcellx",
    "url": "https://finnhub.io/api/news?id=6f058e6a81d8e1f75d4e54ce8910941b4208381db1bf7d7f05df6c4b5049e3a9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771847216,
      "headline": "What Gilead Is Getting Through The Acquisition Of Arcellx",
      "id": 139185670,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=6f058e6a81d8e1f75d4e54ce8910941b4208381db1bf7d7f05df6c4b5049e3a9"
    }
  },
  {
    "ts": null,
    "headline": "Blackstone Life Sciences Enters Co-Funding Agreement With Johnson & Johnson To Advance Oral Menin Inhibitor Bleximenib In AML Trials",
    "summary": "Blackstone Life Sciences Enters Co-Funding Agreement With Johnson & Johnson To Advance Oral Menin Inhibitor Bleximenib In AML Trials",
    "url": "https://finnhub.io/api/news?id=030ac602296e98cc72aee16aa10c30a32a24f570c6962c661d0e445aa52b2803",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771834180,
      "headline": "Blackstone Life Sciences Enters Co-Funding Agreement With Johnson & Johnson To Advance Oral Menin Inhibitor Bleximenib In AML Trials",
      "id": 139184670,
      "image": "",
      "related": "JNJ",
      "source": "Benzinga",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=030ac602296e98cc72aee16aa10c30a32a24f570c6962c661d0e445aa52b2803"
    }
  },
  {
    "ts": null,
    "headline": "LRGF: Low-Cost Multi-Factor ETF With Average Results",
    "summary": "LRGF employs a multi-factor strategy focused on momentum, quality, value, low volatility, and size, underperforming the Russell 1000. See why LRGF ETF is a hold.",
    "url": "https://finnhub.io/api/news?id=c648ec819aff99fe772408928a12fe811efc972f93d63e2a80f20129cdc18568",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771817101,
      "headline": "LRGF: Low-Cost Multi-Factor ETF With Average Results",
      "id": 139181877,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2250494707/image_2250494707.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "LRGF employs a multi-factor strategy focused on momentum, quality, value, low volatility, and size, underperforming the Russell 1000. See why LRGF ETF is a hold.",
      "url": "https://finnhub.io/api/news?id=c648ec819aff99fe772408928a12fe811efc972f93d63e2a80f20129cdc18568"
    }
  },
  {
    "ts": null,
    "headline": "Reported Saturday, Johnson & Johnson's TREMFYA Maintains 80% Clinical Remission And 53% Endoscopic Remission In Ulcerative Colitis Through Week 140 Of Long-Term QUASAR Extension Study",
    "summary": "Reported Saturday, Johnson & Johnson's TREMFYA Maintains 80% Clinical Remission And 53% Endoscopic Remission In Ulcerative Colitis Through Week 140 Of Long-Term QUASAR Extension Study",
    "url": "https://finnhub.io/api/news?id=edfae073ab4a80e79a588fa1502edb80e57d834bbd0f5f78831edf35cf8b2d0d",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771815288,
      "headline": "Reported Saturday, Johnson & Johnson's TREMFYA Maintains 80% Clinical Remission And 53% Endoscopic Remission In Ulcerative Colitis Through Week 140 Of Long-Term QUASAR Extension Study",
      "id": 139184671,
      "image": "",
      "related": "JNJ",
      "source": "Benzinga",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=edfae073ab4a80e79a588fa1502edb80e57d834bbd0f5f78831edf35cf8b2d0d"
    }
  }
]